Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PPIA | P62937 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244146 | 0.91 | MEN1 (0.34) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL3213624 | 0.86 | BTK (0.37) | MEN1MAPK1KMT2ABTKDPP8 | |
| SCHEMBL16118624 | 0.85 | MEN1 (0.40) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL20940177 | 0.85 | MEN1 (0.35) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL1536746 | 0.84 | MEN1 (0.37) | MEN1MAPK1KMT2AHSD11B1BTK | |
| SCHEMBL20940025 | 0.82 | MEN1 (0.32) | MEN1MAPK1KMT2ABTKPPIA | |
| SCHEMBL1933747 | 0.81 | MEN1 (0.39) | MEN1MAPK1KMT2AHSD11B1PPIA | |
| SCHEMBL18216705 | 0.81 | BTK (0.35) | MEN1MAPK1KMT2ABTKDPP8 | |
| SCHEMBL5804382 | 0.78 | MEN1 (0.51) | MEN1MAPK1KMT2AHSD11B1DPP8 | |
| SCHEMBL19747528 | 0.76 | KMT2A (0.38) | MEN1MAPK1KMT2ABTKDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2121626-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | MEN1 2892/4885MAPK1 3992/4885KMT2A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.